» Articles » PMID: 34782929

Exocrine Pancreas Function is Impaired in Adult Relatives of Patients with Type 1 Diabetes

Abstract

Aims: Alterations of the exocrine pancreas have been reported in type 1 diabetes, but their contribution to the pathogenesis of the disease is poorly understood. Here, we investigated markers of exocrine pancreas dysfunction in individuals at-risk of developing type 1 diabetes.

Methods: Serum P-amylase and lipase levels were assessed in samples obtained from healthy controls, patients with new onset type 1 diabetes, relatives participating to the TrialNet Pathway to Prevention who were, at blood collection, autoantibody negative or positive for a single autoantibody (low-risk individuals), and positive for multiple autoantibodies (high-risk individuals). Linear mixed models were adopted to estimate variation of pancreatic enzymes among the groups and to evaluate the influence of high-risk HLA genotypes and residual beta cell function on exocrine pancreas function.

Results: In adults, but not children, reduced levels of P-amylase and lipase were shown in at-risk individuals, including (for P-amylase levels only) those at low-risk, and in T1Dnew. Furthermore, while high-risk HLA genotypes negatively affected P-amylase levels in autoantibody negative adult individuals, fasting C-peptide levels did not correlate with pancreatic enzyme levels.

Conclusions: Exocrine pancreas dysfunction precedes the onset of type 1 diabetes in adult at-risk individuals and may be unrelated to fasting C-peptide levels.

Citing Articles

Serological markers of exocrine pancreatic function are differentially informative for distinguishing individuals progressing to type 1 diabetes.

Williams M, Grace C, Posgai A, McGrail K, Brusko M, Haller M BMJ Open Diabetes Res Care. 2025; 13(1.

PMID: 39755561 PMC: 11749058. DOI: 10.1136/bmjdrc-2024-004655.


Serum exocrine pancreas enzymes are biomarkers of immunotherapy response in new-onset type 1 diabetes.

Bruggeman B, Gornisiewicz S, Bacher R, McGrail K, Campbell-Thompson M, Wasserfall C Front Endocrinol (Lausanne). 2024; 15:1497373.

PMID: 39678192 PMC: 11637828. DOI: 10.3389/fendo.2024.1497373.


Screening for undiagnosed pancreatic exocrine insufficiency (PEI) in a cohort of diabetic patients using faecal elastase testing and PEI scoring system.

Parihar V, Ballester R, Ridgway P, Conlon K, Gibney J, Ryan B Acta Diabetol. 2024; 61(10):1301-1307.

PMID: 38796828 PMC: 11486769. DOI: 10.1007/s00592-024-02307-z.


Type 1 Diabetes: A Disorder of the Exocrine and Endocrine Pancreas.

Bruggeman B, Schatz D J Cell Immunol. 2024; 5(4):120-126.

PMID: 38390030 PMC: 10883315. DOI: 10.33696/immunology.5.177.


The importance of biomarker development for monitoring type 1 diabetes progression rate and therapeutic responsiveness.

Fyvie M, Gillespie K Front Immunol. 2023; 14:1158278.

PMID: 37256143 PMC: 10225507. DOI: 10.3389/fimmu.2023.1158278.


References
1.
Laterza L, Scaldaferri F, Bruno G, Agnes A, Boskoski I, Ianiro G . Pancreatic function assessment. Eur Rev Med Pharmacol Sci. 2014; 17 Suppl 2:65-71. View